Navigation Links
NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
Date:12/2/2009

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the 2009 H1N1 vaccine, the potential use of any data from clinical trials and other anticipated milestones in Mexico and other countries, including the U.S. and the E.U., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including full and complete clinical trial results, which may not be sufficient for regulatory approval in Mexico or may indicate safety concerns not yet encountered; even if the subset results reported today or other final and complete results of the planned clinical trial are positive, the data may not be accepted by regulatory bodies in the U.S., the E.U. or other countries or the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; if approved by the Mexican government, approval of the 2009 H1N1 vaccine may not be timely and thus may not be granted until after the 2009/2010 influenza season has ended; sales of the 2009 H1N1 vaccine are not scheduled to begin in Mexico until late in the 2009/2010 influenza season which could result in poor sales; Avimex is expected to be responsible for sales of the 2009 H1N1 vaccine in Mexico, thus, the Company would be dependent on Avimex's sales effort; Xcellerex, a third party manufacturer engaged to produce commercial quantities of the 2009 H1N1 vaccine, has not manufactured the Company's 2009 H1N1 vaccine at commercial levels and the
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
... Aug. 23 /PRNewswire-FirstCall/ -- Today at ... FUJIFILM Medical Systems U.S.A., Inc. announced that it ... D-EVO™ flat panel detector.  As U.S. installations of ... departments will begin benefiting from the seamless transition ...
... today announced that it has signed an exclusive agreement ... tablets) 10 mcg.  Under the terms of the agreement, ... in the U.S. beginning August 2 through the company,s ... Vagifem® 10 mcg to the U.S. market earlier this ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ is Now Available and Shipping 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 3
(Date:9/30/2014)... Somerset, N.J. (PRWEB) September 30, 2014 ... global provider of advanced delivery technologies and development ... today announced a full agenda for the 25th ... Paris, France, from October 6th to 9th. , ... and supply capability expansions during the show, including ...
(Date:9/30/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on 5 reasons why relapse shouldn’t stand in the way ... a one-time event, like reaching the finish line of a ... “It’s an ongoing process and a lifelong commitment that will ...
(Date:9/30/2014)... devised a way to rapidly test hundreds of different ... discover promising new ways to deliver a class of ... DNA, to human patients. , In a study appearing ... used this technology to identify materials that can efficiently ... type of high-speed screen could help overcome one of ...
(Date:9/30/2014)... cells cannot multiply and cardiac muscles contain few ... itself after a heart attack. Now Tel Aviv ... standard in cardiac tissue engineering. , Dr. Tal ... TAU,s Department of Biotechnology, Department of Materials Science ... have been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 RISC ... IT Infrastructure analytics across data center, cloud and ... achieved an important milestone of helping more than ... for important projects such as IT infrastructure transformation, ... , The strong customer engagement rates and partner ...
Breaking Medicine News(10 mins):Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 2Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 3Health News:High-speed drug screen 2Health News:High-speed drug screen 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3
... methodology behind WHO rankings, WASHINGTON, Feb. 26 ... in what could be,the final debate before the nominee ... be a topic of discussion. But as the two ... tales of people (invariably,swing state residents) encountered on the ...
... YORK (Feb. 26, 2008) -- As many as ... not respond to the standard first-line chemotherapy placed ... data. When this happens, typically, their only option ... at the Herbert Irving Comprehensive Cancer Center of ...
... Feb. 26 ULLICO Casualty Group (ULLICO,Casualty) has ... fiduciary and union liability insurance programs. Hudson is ... than $2,billion) by A.M. Best Company. Hudson is ... the holding company for one of the world,s,largest ...
... provoked soil-dwelling bacteria into producing a new type of ... in a battle for survival. , The antibiotic holds ... ulcers in humans. Also, figuring out the still murky ... help scientists develop strategies for finding other new antibiotics. ...
... Board: HFIT), a leading employee health improvement company,will report ... 31, 2007, on Wednesday, March 5, 2008, after the ... a conference call to discuss the,results the same day. ... and chief executive officer, and Wes Winnekins, chief financial,officer., ...
... 26 At Beverly Hills,Liposculpture, Dr. Alan Bittner ... safe breast reduction surgery that can reduce,breasts by ... The procedure,called liposculpture breast reduction, takes approximately 90 ... fat (more than 3 coke cans!) from each ...
Cached Medicine News:Health News:World Health Report Rankings Driven by Ideology, Skewed Data 2Health News:Study looks at new bladder cancer therapy for patients unresponsive to standard treatment 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 3Health News:Bacterial 'battle for survival' leads to new antibiotic 2Health News:Bacterial 'battle for survival' leads to new antibiotic 3Health News:Health Fitness Corp. to Report Fourth Quarter and Year End 2007 Financial Results on March 5, 2008 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 3
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Medicine Products: